Quanterix Corporation has completed its acquisition of Akoya Biosciences, creating what the company describes as the first integrated platform capable of measuring biomarkers across both blood and tissue. The transaction establishes a scaled leader in early disease detection for neurology, oncology, and immunology markets.
Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash to holders of Akoya shares and other equity awards.
Market Expansion and Strategic Vision
The acquisition significantly expands Quanterix's market reach, with CEO Masoud Toloue, PhD, stating that the transaction "extends our portfolio into new markets and is expected to expand our served addressable market from $1 billion to $5 billion." The combined entity aims to deliver comprehensive protein biomarker solutions that leverage signatures in both blood and tissue, providing what Toloue describes as "a more holistic and predictive view of a patient's disease."
The company projects that the combined business will benefit from significant scale, a strong balance sheet, and an accelerated path to profitability by 2026.
Leadership and Governance Changes
Masoud Toloue and Vandana Sriram will continue to serve as Chief Executive Officer and Chief Financial Officer of the combined company. The merger brings strategic leadership additions to the Quanterix Board of Directors, with Akoya designating two directors to join the board.
Scott Mendel, who brings over 30 years of financial and operational experience and most recently served as CEO and President of GenMark Diagnostics, has been appointed to the board. Dr. Myla Lai-Goldman, described as a pioneer and leader in the diagnostics industry with various leadership roles at Labcorp and its predecessor company Roche Biomedical Laboratories, also joins the board.
These appointments replace Martin D. Madaus, PhD, and Sarah Hlavinka, who resigned from the Quanterix Board of Directors immediately prior to the transaction closing.
Financial Position and Technology Platform
At the time of closing, Quanterix maintained approximately $163 million in cash after repayment of Akoya's debt and transaction-related costs, providing a strong financial foundation for the combined entity.
The acquisition builds upon Quanterix's existing Simoa® technology, which has established what the company calls the gold standard for earlier biomarker detection in blood, serum, or plasma. The technology can quantify proteins far lower than the Level of Quantification (LoQ) and has supported research published in more than 3,400 peer-reviewed journals over nearly two decades.
Research and Clinical Applications
The combined platform addresses disease understanding and management across multiple therapeutic areas, including neurology, oncology, immunology, cardiology, and infectious disease. Quanterix's industry-leading precision instruments, digital immunoassay technology, and CLIA-certified Accelerator laboratory provide the infrastructure for this expanded capability.
The integration creates opportunities for more comprehensive biomarker analysis by combining Quanterix's blood-based detection capabilities with Akoya's tissue-based technologies, potentially enabling more precise disease characterization and monitoring across the continuum of patient care.
